From diabetes to dopamine: Evaluating the disease-modifying potential of GLP-1 receptor agonists in Parkinson's disease. A systematic review and meta-analysis of placebo-controlled trials.
Saved in:
| Title: | From diabetes to dopamine: Evaluating the disease-modifying potential of GLP-1 receptor agonists in Parkinson's disease. A systematic review and meta-analysis of placebo-controlled trials. |
|---|---|
| Authors: | Badran, Ahmed Samy (AUTHOR), Gbreel, Mohamed Ibrahim (AUTHOR) |
| Source: | Neurological Sciences. Nov2025, Vol. 46 Issue 11, p5643-5655. 13p. |
| Subjects: | Glucagon-like peptide-1 receptor, Parkinson's disease, Glucagon-like peptide-1 agonists, Statistical significance, Appetite loss |
| Abstract: | Background: While current therapies address symptom management, there is an unmet need for disease-modifying treatments in Parkinson's disease (PD). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for diabetes, have shown neuroprotective properties. Aim: To assess the disease-modifying potential and safety of GLP-1 RAs in PD. Methods: We followed Cochrane Handbook. We included all randomized controlled trials (RCTs) evaluating GLP-1 RAs in PD that were identified through comprehensive database searches through March 2025. Cochrane's risk-of-bias tool was used to assess the RCTs' quality. A random-effects model was used to calculate mean differences (MDs) and risk ratios (RRs) with their confidence intervals (CIs) and analyze them using R. Results: Our meta-analysis of four placebo-controlled RCTs found that GLP-1 RAs demonstrated a statistically significant overall improvement in ON-medication motor scores (MDS-UPDRS Part III: MD -0.75, 95% CI [-1.50, -0.0009]; P = 0.04). However, this benefit was not consistently observed at individual follow-up time points. In contrast, the pooled analysis for OFF-medication motor scores showed no significant overall improvement (MD -1.39; P = 0.16), despite considerable heterogeneity; only the 60-week follow-up showed a significant benefit (MD -3.0; P = 0.005). No significant differences were found for health-related quality of life (PDQ-39), other MDS-UPDRS domains (Part I, Part II, or Part IV), or Levodopa equivalent daily dose. GLP-1 RAs were associated with significantly higher rates of gastrointestinal adverse events (loss of appetite, nausea, vomiting, dyspepsia, gastroesophageal reflux) and weight loss. Conclusions: Current evidence does not sufficiently support the routine use of GLP-1 RAs for motor improvement in PD. [ABSTRACT FROM AUTHOR] |
| Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 188779327 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: From diabetes to dopamine: Evaluating the disease-modifying potential of GLP-1 receptor agonists in Parkinson's disease. A systematic review and meta-analysis of placebo-controlled trials. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Badran%2C+Ahmed+Samy%22">Badran, Ahmed Samy</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gbreel%2C+Mohamed+Ibrahim%22">Gbreel, Mohamed Ibrahim</searchLink> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Neurological+Sciences%22">Neurological Sciences</searchLink>. Nov2025, Vol. 46 Issue 11, p5643-5655. 13p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Glucagon-like+peptide-1+receptor%22">Glucagon-like peptide-1 receptor</searchLink><br /><searchLink fieldCode="DE" term="%22Parkinson's+disease%22">Parkinson's disease</searchLink><br /><searchLink fieldCode="DE" term="%22Glucagon-like+peptide-1+agonists%22">Glucagon-like peptide-1 agonists</searchLink><br /><searchLink fieldCode="DE" term="%22Statistical+significance%22">Statistical significance</searchLink><br /><searchLink fieldCode="DE" term="%22Appetite+loss%22">Appetite loss</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Background: While current therapies address symptom management, there is an unmet need for disease-modifying treatments in Parkinson's disease (PD). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for diabetes, have shown neuroprotective properties. Aim: To assess the disease-modifying potential and safety of GLP-1 RAs in PD. Methods: We followed Cochrane Handbook. We included all randomized controlled trials (RCTs) evaluating GLP-1 RAs in PD that were identified through comprehensive database searches through March 2025. Cochrane's risk-of-bias tool was used to assess the RCTs' quality. A random-effects model was used to calculate mean differences (MDs) and risk ratios (RRs) with their confidence intervals (CIs) and analyze them using R. Results: Our meta-analysis of four placebo-controlled RCTs found that GLP-1 RAs demonstrated a statistically significant overall improvement in ON-medication motor scores (MDS-UPDRS Part III: MD -0.75, 95% CI [-1.50, -0.0009]; P = 0.04). However, this benefit was not consistently observed at individual follow-up time points. In contrast, the pooled analysis for OFF-medication motor scores showed no significant overall improvement (MD -1.39; P = 0.16), despite considerable heterogeneity; only the 60-week follow-up showed a significant benefit (MD -3.0; P = 0.005). No significant differences were found for health-related quality of life (PDQ-39), other MDS-UPDRS domains (Part I, Part II, or Part IV), or Levodopa equivalent daily dose. GLP-1 RAs were associated with significantly higher rates of gastrointestinal adverse events (loss of appetite, nausea, vomiting, dyspepsia, gastroesophageal reflux) and weight loss. Conclusions: Current evidence does not sufficiently support the routine use of GLP-1 RAs for motor improvement in PD. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=188779327 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s10072-025-08411-4 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 13 StartPage: 5643 Subjects: – SubjectFull: Glucagon-like peptide-1 receptor Type: general – SubjectFull: Parkinson's disease Type: general – SubjectFull: Glucagon-like peptide-1 agonists Type: general – SubjectFull: Statistical significance Type: general – SubjectFull: Appetite loss Type: general Titles: – TitleFull: From diabetes to dopamine: Evaluating the disease-modifying potential of GLP-1 receptor agonists in Parkinson's disease. A systematic review and meta-analysis of placebo-controlled trials. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Badran, Ahmed Samy – PersonEntity: Name: NameFull: Gbreel, Mohamed Ibrahim IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 11 Text: Nov2025 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 15901874 Numbering: – Type: volume Value: 46 – Type: issue Value: 11 Titles: – TitleFull: Neurological Sciences Type: main |
| ResultId | 1 |
